Ansa Biotechnologies
New accelerator entry · 2022-08-20 · the record
In their words
Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods. Currently, DNA is manufactured via a chemical method that has remained mostly unchanged for 35 years. Our enzyme-based approach promises to dramatically accelerate innovation in biological research and biotechnology, including therapeutics, diagnostics and biomanufacturing.
What the record says
- One of 34 companies held here in Healthcare › Industrial Bio.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Ansa Biotechnologies
- Source Check — verify what Ansa Biotechnologies states, against the registers that hold it.
- INVEST — size up this company on the figures its record states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Ansa Biotechnologies for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Ansa BiotechnologiesYou get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Ansa Biotechnologies: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. FoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.